Critical Review of Growth Factors as Clinical Tools in Primary and Metastatic Breast Cancer

摘要: Present research in the field of clinical breast cancer is focused on new diagnostic methods and development treatment modalities [25]. Adjuvant systemic therapy with chemotherapeutic drugs or endocrine has been shown to result a 25% reduction annual odds death, meaning an absolute decrease death 4% 10% nodenegative node-positive patients, respectively [13] (reprinted part this volume). However, it must be concluded that majority patients primary will overtreated cases adjuvant therapy. Both efficacy cost effectiveness are presently important subjects debate [20, 27]. Identification high-risk low-risk therefore major issue. For large series classical modern prognostic factors (Table 1) have reported [18, 23, 28, 29]. These concern patient characteristics parameters determined blood tumor characteristics. Most these evaluated respect relapse-free survival (RFS) overall (OS), but very few response hormonal chemotherapy metastatic disease. also for recurrent disease (macrometastases) predictors clinically reaching decisions concerning type